These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12885889)

  • 1. Oral immunogenicity of human papillomavirus-like particles expressed in potato.
    Warzecha H; Mason HS; Lane C; Tryggvesson A; Rybicki E; Williamson AL; Clements JD; Rose RC
    J Virol; 2003 Aug; 77(16):8702-11. PubMed ID: 12885889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of human papillomavirus type 16 virus-like particles in transgenic plants.
    Biemelt S; Sonnewald U; Galmbacher P; Willmitzer L; Müller M
    J Virol; 2003 Sep; 77(17):9211-20. PubMed ID: 12915537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
    Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
    J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
    Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
    BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
    Gerber S; Lane C; Brown DM; Lord E; DiLorenzo M; Clements JD; Rybicki E; Williamson AL; Rose RC
    J Virol; 2001 May; 75(10):4752-60. PubMed ID: 11312347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.
    Rose RC; Lane C; Wilson S; Suzich JA; Rybicki E; Williamson AL
    Vaccine; 1999 Apr; 17(17):2129-35. PubMed ID: 10367945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillomavirus-like particles and HPV vaccine development.
    Schiller JT; Lowy DR
    Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
    Chen Y; Ghim SJ; Jenson AB; Schlegel R
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2137-46. PubMed ID: 9747722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.
    Rose RC; Bonnez W; Da Rin C; McCance DJ; Reichman RC
    J Gen Virol; 1994 Sep; 75 ( Pt 9)():2445-9. PubMed ID: 8077946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Assembling Plant-Derived Vaccines Against Papillomaviruses.
    Noris E
    Methods Mol Biol; 2018; 1776():85-95. PubMed ID: 29869236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.